New combo attack on lung cancer brain tumors shows promise in early trial

NCT ID NCT06248606

Recruiting now Disease control Sponsor: Ryan Gentzler, MD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive both treatments. The main goal is to see how many patients have their brain tumors shrink or stop growing after 3 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Virginia Health System
RECRUITING

Charlottesville, Virginia, 22908, United States

Contact Email: •••••@•••••

Contact
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

KRAS G12C KRAS G12C NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NSCLC